Abstract | Allogeneic haematopoietic stem cell transplantation is used to treat a variety of disorders, but its efficacy is limited by the occurrence of graft-versus-host disease (GVHD). The past decade has brought impressive advances in our understanding of the role of stimulatory and suppressive elements of the adaptive and innate immune systems from both the donor and the host in GVHD pathogenesis. New insights from basic immunology, preclinical models and clinical studies have led to novel approaches for prevention and treatment. This Review highlights the recent advances in understanding the pathophysiology of GVHD and its treatment, with a focus on manipulations of the immune system that are amenable to clinical application.
Allogeneic haematopoietic stem cell transplantation (HSCT) is the only curative option for many haematological malignancies. However, the development of graft-versushost disease (GVHD) limits the success of allogeneic HSCT and is fatal to approximately 15% of transplant recipients 1 . GVHD results from immunological attack on target recipient organs or tissues (such as the skin, liver and gut) by donor allogeneic T cells that are transferred along with the allograft. The development and severity of GVHD in transplant recipients depends on factors such as recipient age, toxicity of the conditioning regimen, haematopoietic graft source and GVHD prophylaxis approaches. Steroids are the first line of treatment, but patients with steroid-refractory acute GVHD have a dismal outcome, with long-term mortality rates that can reach 90%.
Chronic GVHD -which was originally defined as occurring after the first 100 days post-HSCT -is now known to have a characteristic clinical presentation, which resembles autoimmune vascular diseases and is distinct from that of acute GVHD. Chronic GVHD occurs in 30-65% of allogeneic HSCT recipients, can be highly debilitating in its extensive form and has a 5-year mortality rate of 30-50% that is mainly due to immune dysregulation and opportunistic infections.
Prior to HSCT, recipients undergo a conditioning regimen that is myelosuppressive (to deplete host stem cells and make space for donor stem cell engraftment) and immunosuppressive (to reduce graft rejection mediated by host immune cells). However, the toxicity and suppressive effects of this regimen can cause tissue damage and induce inflammation in the host, and these effects can precipitate GVHD. Approaches to reduce the intensity of conditioning regimens (for example, by using non-myeloablative conditioning regimens) or localize the treatment (for example, through total lymph node irradiation) have led to a reduction in the incidence and improved prophylaxis of acute GVHD 2, 3 . Reducedintensity conditioning regimens rely on the beneficial graft-versus-tumour effects (GVT effects) (BOX 1) of the transplant to eliminate residual malignant cells. The maintenance of the beneficial GVT activity in HSCT recipients with malignancies is therefore an important consideration in the development of conditioning regimens and treatments for GVHD.
This Review provides an update on our current knowledge of GVHD pathogenesis, as gleaned from preclinical models, and focuses on the most promising therapeutic targets at each stage of the multistep GVHD pathogenesis process. These targets include T cellantigen-presenting cell (APC) interactions, T cell activation pathways, pro-inflammatory cytokines and T cell trafficking pathways.
Overview of GVHD pathogenesis GVHD was initially reported by Barnes, Loutit and Micklem and classically defined by Billingham as a syndrome in which donor immunocompetent cells recognize and attack host tissues in immunocompromised allogeneic recipients 4, 5 . Acute GVHD and chronic GVHD involve distinct pathological processes: acute GVHD has strong inflammatory components (FIG. 1) , whereas chronic GVHD displays more autoimmune and fibrotic features (FIG. 2) . Acute GVHD was
Allogeneic haematopoietic stem cell transplantation
A transplant with allogeneic haematopoietic stem cells (HSCs) is a treatment in which the transplanted HSCs are obtained from a normal donor. This approach can be used to treat either malignant or non-malignant disorders. Mismatches between the histocompatibility antigens of the donor and patient can lead to adverse events, such as rejection of the transplanted graft or pathological immune responses to normal tissues in the patient.
Conditioning regimen
(Also known as a preparative regimen). A combination of chemotherapy, radiation therapy and/or immunosuppressive medications that is designed not only to destroy residual malignant cells, but also to provide space for donor stem cell engraftment and to provide immunosuppression to prevent host rejection of the donor stem cells.
Myelosuppressive
Refers to conditioning regimens that abrogate bone marrow activity, resulting in a marked decrease in the production of blood cells and platelets.
thought to be a process driven mainly by T helper 1 (T H 1)-and T H 17-type immune responses, whereas chronic GVHD was thought to be predominately mediated by T H 2-type responses. However, this paradigm has been challenged by recent mouse and human studies and is not absolute [6] [7] [8] [9] [10] [11] . Acute GVHD involves alloreactive donor T cell-mediated cytotoxic responses against the tissues of the recipient, mediated by cell-surface and secreted factors 12 . The pivotal role of T cells in acute GVHD is supported by the complete abrogation of GVHD following T cell depletion from the graft, an approach that remains the most effective in preventing acute GVHD. Tissue damage caused by the cytotoxic T cells leads to the recruitment of other effector cells (including natural killer (NK) cells and neutrophils), which further augment tissue injury and result in a selfperpetuating state of GVHD that is difficult to control once it is fully initiated.
Mice are the main model animals used for preclinical studies of GVHD pathogenesis and prevention, although large animal (canine and nonhuman primate) models have also provided significant insights into acute GVHD prevention and therapy, especially using pharmacological agents. Owing to the availability of a plethora of reagents, knockout and transgenic strains, and transplantable tumour cell lines to assess antitumour effects, mouse models have facilitated a thorough mechanistic dissection of the immunological processes of GVHD. Mouse models of acute GVHD usually involve the transplantation of bone marrow (as a source of haematopoietic stem cells), supplemented with varying numbers and different types of donor lymphocytes, into irradiated allogeneic recipients that differ from the donors in their MHC class I and/or class II molecules or in multiple minor histocompatibility antigens. Current models of chronic GVHD include mice that develop sclerodermatous, autoantibody-mediated or lupus-like diseases, as well as diseases associated with thymic dysfunction 13 . Because none of these models recapitulates all of the diverse characteristics of human chronic GVHD, there has been a relative paucity of drug candidates for the treatment of the growing population of patients with chronic GVHD. However, new models have been developed to study a wider range of target organs, including the lungs 14 . Besides the species differences between mice and humans, there are other factors to consider when using mouse models of GVHD. Mouse strain combination choice can have a marked impact on the type, severity and pathophysiology of GVHD 12 . In addition, differences in the vendor, age, sex, genetic drift and gut microbiota of the mice and in the transplant protocols used by different laboratories can each have a marked effect on GVHD pathophysiology. Nonetheless, mouse models have proved to be extremely useful for developing and testing new treatment approaches.
Role of innate immune responses. With our improved understanding of the induction of innate and adaptive immune responses by microbial products, the impact of the gut microbiome on GVHD is receiving increased attention. Current data implicate the innate immune response as being responsible for initiating or amplifying acute GVHD. Molecules such as bacterial lipopolysaccharide (LPS) that are released from the injured gut during the conditioning regimen activate innate immune receptors, including Toll-like receptors (TLRs), and cause a cytokine storm, which favours the development of acute GVHD 15 . Mutations in TLR4 (which encodes an LPS receptor) have been shown in mice and patients to reduce GVHD risk 16 , and ligation of TLR9 by bacterial DNA can increase the induction of acute GVHD 17, 18 . In the clinical setting, polymorphisms of the genes encoding TLR4 and NOD-like receptors (NLRs) such as nucleotide-binding oligomerization domain protein 2 (NOD2) are associated with a higher GVHD incidence and might explain the seemingly unpredictable incidence of GVHD. NOD2 and the TLR5 ligand flagellin have been shown to have an inhibitory effect on GVHD by suppressing the function of APCs and favouring the generation of regulatory T (T Reg ) cells 19, 20 . One of the most direct lines of evidence for the effects of TLRs on GVHD was derived by applying an activator of TLR7 to mouse skin before inducing GVHD. This resulted in massive T cell infiltrates and GVHD pathology only at the site of pretreated skin 21 . A role for TLR9 and its downstream signalling adaptor MYD88 (myeloid differentiation primary-response protein 88) was observed in an intestinal GVHD model 18 . Increased proportions of enterobacteria, enterococci, Bacteroides spp. and Prevotella spp. in the gut microbiota have been observed in mouse models of colitis and ileitis and are suspected to modulate innate immune responses via TLRs 22, 23 . Thus, manipulation of the gut flora to make it 'less GVHD favourable' might be a way to ameliorate GVHD, as suggested by the decreased severity of GVHD and improved survival of animals following the administration of probiotic bacteria 24 . Together, these data suggest that MYD88 inhibitors (such as ST2825) may be useful in reducing the innate and adaptive immune responses that are triggered by TLR activation during GVHD 25 .
Box 1 | GVHD versus GVT effects
The long-known beneficial effect of graft-versus-host disease (GVHD) on the incidence of leukaemia relapse and the overall survival of patients with leukaemia is known as the graft-versus-tumour (GVT) effect 172 . The role of T cells in both GVHD and the GVT effect was supported by the finding that T cell depletion from the graft eliminates GVHD but at the expense of an increased leukaemia relapse rate 173 . With the increasing use of non-myeloablative or reduced-intensity conditioning regimens for allogeneic haematopoietic stem cell transplantation, there is an increased reliance on immune-mediated GVT effects to control the underlying disease.
The major GVT effectors are cytotoxic T cells that recognize allogeneic histocompatibility antigens and unique tumour antigens. In addition, natural killer (NK) cells and NKT cells can directly recognize MHC class I molecules and stress-induced peptides and mount antitumour responses. Current strategies to improve GVT effects are based on selectively targeting tumour-specific killing and inhibiting immune escape mechanisms commonly used by tumours. These immune escape mechanisms include: the loss of tumour-specific molecules or presented peptides; the downregulation or loss of MHC class I or co-stimulatory molecule expression by tumour cells; the induction of functional defects in T cells or NK cells; the production of soluble inhibitors of NK cell function; the expression of death receptor ligands such as CD95 ligand by tumour cells; and tumour cell resistance to apoptosis. The initiation and maintenance of acute graft-versus-host disease (GVHD) has been conceptualized into four phases with positive feedback loops that perpetuate the process. Although the conditioning phase is not absolutely necessary for the induction of acute GVHD, in many of the models it activates antigen-presenting cells (APCs), via tissue destruction, and increases APC function. Through the release of gut bacteria, pathogen-associated molecular patterns (PAMPs) and chemokines, the conditioning phase can also lead to the activation of innate immune cells that participate in direct tissue damage and contribute to the cytokine storm. Host haematopoietic APCs probably have the most important role in the initiation of GVHD, but this may depend on the model; the potential role of donor APCs and host non-haematopoietic APCs should not be ignored. Following the presentation of antigens to T cells, a strong cytokine response is initiated. These cytokines further promote antigen presentation and the recruitment of effector T cells and innate immune cells, which further augment the pro-inflammatory cytokine milieu. Finally, the effector T cells, natural killer (NK) cells, macrophages and pro-inflammatory cytokines (such as tumour necrosis factor (TNF)) result in end-organ damage, which is clinically recognized as acute GVHD in the skin, lungs, gut and liver. The resulting tissue damage, if not treated, will further amplify the process to more severe stages of GVHD pathology, which are extremely difficult to control. CTL, cytotoxic T lymphocyte; IFNγ, interferon-γ; TLR, Toll-like receptor.
Non-myeloablative
Refers to conditioning regimens that do not fully ablate bone marrow activity, resulting in no decrease (or at most a modest decrease) in the production of blood cells and platelets. Such regimens still help with engraftment and prevent the rejection of donor cells.
Graft-versus-tumour effects
(GVT effects). The antitumour activity of donor T cells against residual malignant cells of the graft recipient following (allogeneic) bone marrow transplantation.
Minor histocompatibility antigens
Normal proteins that are polymorphic in a given population. Even when a transplant donor and recipient are identical with respect to their MHC genes, the amino acid differences in minor proteins can cause graft solid-organ tissue to be slowly rejected.
Genetic drift
The process of change in the genetic composition of a population owing to chance or random events rather than natural selection, resulting in changes in allele frequencies over time.
Other molecules, known as damage-associated molecular patterns (DAMPs), which are released following conditioning regimen-induced tissue damage, may have a role in the induction of GVHD. For example, dying cells in the guts of mice and the peritoneal fluid of patients with GVHD release ATP, which binds to its receptor P2X7 on host APCs and activates the inflammasome. This leads to upregulation of the expression of co-stimulatory molecules by APCs 26 . Pharmacological blockade of P2X7 decreases the incidence of acute GVHD and increases the number of T Reg cells. Furthermore, polymorphisms in the gene encoding P2X7 are associated with survival differences among patients who receive allogeneic HSCT, which supports the possibility that blockade of P2X7 signalling may be a useful strategy to prevent or treat GVHD 27 . It is important to mention that despite the prominent role of the innate immune system in the pathogenesis of GVHD, T cells can still be activated and GVHD can still occur in the absence of appropriate TLR signalling 28 .
Role of APCs.
There has been great progress recently in discerning the role of APCs and their subsets, and the importance of their origin (donor or host), in GVHD and GVT responses (for GVT effects, see BOX 1) . The presentation of minor histocompatibility antigens by MHC class I molecules on recipient haematopoietic APCs is important, although not required, for CD8 + T cell-dependent acute GVHD. Donor APCs can augment this response 29, 30 . MHC class II-bearing host haematopoietic APCs were previously thought to be essential for the induction of CD4 + T cell-dependent acute GVHD, but this has been called into question [31] [32] [33] [34] . Recent studies have shown that host haematopoietic professional APCs in lymphoid organs may have only a limited capacity to induce GVHD, and host dendritic cells (DCs) may not be required [35] [36] [37] . Parenchymal tissue cells can acquire APC functions and have been shown to promote marked expansion of alloreactive donor T cell populations in the gastrointestinal tract. In the absence of functional host haematopoietic APCs, the presentation of minor histocompatibility There is immune deviation to a T H 2-type cytokine response (c), which includes the production of interleukin-4 (IL-4), IL-5 and IL-11. This response leads to the release of fibrogenic cytokines -such as IL-2, IL-10 and transforming growth factor-β1 (TGFβ1) -and the activation of macrophages that produce platelet-derived growth factor (PDGF) and TGFβ1 (d). These molecules induce the proliferation and activation of tissue fibroblasts. Low numbers of regulatory T (T Reg ) cells are the fifth hallmark (e), and finally there is B cell dysregulation (f), which leads to the emergence of autoreactive B cells and the production of autoreactive antibodies. It has been suggested that autoreactive B cell activation may be due to the presence of high levels of B cell-activating factor (BAFF) in the lymphoid microenvironment. All these events contribute to an autoimmune-like systemic syndrome that is associated with fibroproliferative changes. These changes can occur in almost any organ of the body but mainly affect oral and ocular mucosal surfaces and the skin, lungs, kidneys, liver and gut. antigens by donor haematopoietic APCs or host nonhaematopoietic APCs is sufficient for GVHD induction 35, 37 . These data indicate that experimental acute GVHD can be induced by non-haematopoietic recipient APCs, although it is difficult to gauge the impact of these alternative pathways in humans. Because donor and host haematopoietic APCs and host non-haematopoietic APCs can each contribute to GVHD, approaches that selectively deplete a single type of APC, rather than globally impairing APC function, may prove inefficient for the prevention of acute GVHD and, in the case of host haematopoietic APCs, may even be deleterious. Therefore, although a future strategy to prevent GVHD may focus on antigen presentation by APCs, there is no clear approach that can accomplish this goal at the present time.
Targeting B cells
In mouse studies, the depletion of B cells from the graft resulted in a decreased incidence of acute GVHD, perhaps owing to the effect of B cells on host APCs 38 . Paradoxically, B cells can also have a protective role in GVHD by controlling the differentiation of naive T cells into effector T cells and by inhibiting the proliferation of alloantigen-specific effector T cells. These protective effects are mediated through the secretion of interleukin-10 (IL-10) and the induction of allo antigenspecific T Reg cells by B cells 39 . In the clinical setting, incorporating rituximab -a CD20-specific monoclonal antibody that depletes B cells -into the conditioning regimen reduces the incidence and severity of acute GVHD. Moreover, an association between high numbers of donor B cells and the development of both acute and chronic GVHD has been demonstrated 40 , although treatment with rituximab after, instead of before, HSCT did not reduce GVHD incidence 41 . The role of B cells in chronic GVHD is more straightforward and promising, as both preclinical and clinical evidence suggests an important role for B cell dysregulation in chronic GVHD pathogenesis and treatment 42 . Targeting germinal centre formation (using lymphotoxin-β receptor blocking agents) 14 and inhibiting the IL-17-BAFF (B cell-activating factor) axis 43 , which is a cause of B cell dysregulation, are particularly interesting strategies for future clinical intervention(s) in chronic GVHD and are worthy of investigation.
NOD-like receptors
(NLRs). The human NLR family comprises 22 members. They share a domain organization that usually includes an amino-terminal caspaserecruitment domain (CARD) or pyrin domain (PYD), followed by an intermediary nucleotide-binding oligomerization domain (NOD) and carboxy-terminal leucine-rich repeat motifs. NLRs are thought to survey the host cytosol and intracellular compartments for pathogenand damage-associated molecular patterns to activate signalling pathways that contribute to the host innate immune response.
P2X7
An ATP-gated cation channel that is expressed by haematopoietic cells and participates in cell proliferation and apoptosis. It belongs to the family of purinoceptors for ATP and is responsible for the ATP-dependent lysis of macrophages through the formation of membrane pores.
Inflammasome
A large multiprotein complex formed by a NOD-like receptor (NLR), the adaptor protein ASC and pro-caspase 1. The assembly of the inflammasome leads to the activation of caspase 1, which cleaves pro-interleukin-1β (pro-IL-1β) and pro-IL-18 to generate the active pro-inflammatory cytokines.
Germinal centre
A highly specialized and dynamic microenvironment located in peripheral lymphoid tissues (for example, the spleen or lymph nodes). It is the main site of B cell maturation, which leads to the generation of memory B cells and plasma cells that produce high-affinity antibodies.
T H 1 cells 
Targeting T cell responses Both donor CD4
+ and donor CD8 + T cells have crucial roles in the pathogenesis of GVHD. Thus, arguably the most effective approaches for GVHD prevention and therapy will focus on the depletion, tolerization or functional incapacitation of donor T cells. It is important to note that GVHD is a result of naive T cell responses. Central and effector memory T cells do not appear to induce GVHD, although they mediate GVT responses 44 . Clinical trials transferring memory T cells alone are underway at several institutions and may provide a readily exportable and effective approach to GVHD prevention. Owing to their ability to differentiate into various effector T cell subsets -namely, T H 1 cells, T H 2 cells and T H 17 cells -CD4 + T cells are particularly important in the initiation of GVHD in mice and have been considered as potential targets for the treatment and prevention of GVHD in the clinic (TABLE 1) .
T H 1 and T H 2 cell responses.
T H 1 cells and proinflammatory molecules such as IL-1, IL-6, IL-12, tumour necrosis factor (TNF) and nitric oxide have been shown to be aetiological factors in the induction of GVHD 45, 46 . These pro-inflammatory molecules contribute to a systemic syndrome with variable presentations of weight loss, diarrhoea and skin changes, and increased mortality. Although the T H 1 cell-associated cytokines interferon-γ (IFNγ), IL-2 and TNF have been implicated in the pathophysiology of acute GVHD 47 , some studies have reported the opposite effects. IFNγ may regulate immune suppression in addition to supporting cellular cytotoxicity 48 . The impact of IFNγ on acute GVHD may depend on the timing of its production, as IFNγ can have immunosuppressive effects when it is present immediately after HSCT but can exacerbate disease via its pro-inflammatory properties at later stages 49 . In rodents, the neutralization of TNF has been associated with variable benefits in reducing acute GVHD, and a Phase II randomized study of TNF neutral ization in patients with steroid-refractory GVHD demonstrated a relatively low response rate compared with other first-line medications for GVHD 50 . T H 2-type cytokines, such as IL-4, can reduce acute GVHD, but, as in the case of IFNγ, their effects may depend on timing 51, 52 . Mice receiving donor T cells that lack the ability to secrete all four classical T H 2-type cytokines (IL-4, IL-5, IL-9 and IL-13) have enhanced T cell proliferation and increased GVHD severity 53 . However, in studies involving the transfer of donor T cell populations lacking T H 1 cells or T H 2 cells (using Stat4
Stat6
-/-mice, respectively), both subsets were shown to contribute to acute GVHD, although the patterns of tissue injury that developed were distinct 9 . The lack of conclusive and reproducible evidence supporting roles for T H 1 or T H 2 cells in GVHD suggests the involvement of other subsets.
Owing to the paradoxical and variable effects of targeting T H 1-and T H 2-type cytokines, such approaches alone will probably not be sufficient to prevent acute GVHD, but they may serve as adjunct strategies to reduce the tissue injury of GVHD.
T H 17 cell responses. T H 17 cells, which are characterized by the production of IL-17A, IL-17F, IL-21 and IL-22, have been shown to have a direct role in GVHD pathobiology. Initial studies reported that a lack of donor T H 17 cells augmented T H 1 cell differentiation and exacerbated acute GVHD 54 . Other studies have shown that an absence of IL-17 production by donor cells markedly impairs the development of CD4 + T cell-mediated acute GVHD, although this effect was not observed for GVHD mediated by both CD4 + and CD8 + T cells 55 . Adoptive transfer of in vitro-differentiated T H 17 cells resulted in lethal acute GVHD 56 , whereas GVHD was not affected when T H 17 cell differentiation was disrupted through deletion of the gene encoding the T H 17 cell-specific transcription factor RORγt (retinoic acid receptor-related orphan receptor-γt) 57 . These findings demonstrate that T H 17 cells are sufficient but not necessary to induce GVHD. In patients with acute GVHD, IL-17-producing cells can be found in biopsy samples from the gut but not from the skin 6 . Thus, IL-17 may yet prove to be a viable target for neutralization in patients with GVHD in the gut.
The T H 17-type cytokine IL-21 is another potential neutralization target given its role in promoting the activation, differentiation, maturation or expansion of NK cell, B cell, T cell and APC populations. IL-21 has antitumour effects 58 and can facilitate autoimmunity 59 . It also increases T H 17 cell activity not only by directly augmenting T H 17 cell responses 60 but also by inhibiting T Reg cells 61, 62 . Inhibition of IL-21-IL-21 receptor signalling in vivo reduced acute GVHD activity in the gut, and this effect was associated with decreased T H 1 cell and increased T Reg cell numbers in the gut mucosa 63 . A similar outcome was observed using a neutralizing antibody specific for human IL-21 in a human-intomouse xenogeneic model of gut GVHD 64 . The GVT effect was mostly preserved in the absence of IL-21 signalling 65, 66 , although such an effect may not be seen in all tumour models or patients. Nonetheless, based on the available preclinical data, IL-21 neutralization is a particularly attractive approach for preventing and treating acute GVHD and perhaps chronic GVHD in the clinic.
An alternative approach to manipulating the T H 17 cell response is to target the cytokines that are involved in the induction of T H 17 cells, such as IL-6. Together with transforming growth factor-β (TGFβ), IL-6 promotes the differentiation of naive T cells into T H 17 cells, whereas in its absence T Reg cells are induced 67, 68 . Accordingly, high serum levels of IL-6 can be predictive of severe acute GVHD 69 , and IL6 gene polymorphisms are associated with acute GVHD and chronic GVHD in patients 70, 71 . Infusion of an IL-6 receptor-specific monoclonal antibody in a model of acute GVHD led to increased T Reg cell numbers and a reduction in GVHD pathological damage, particularly in the gut 72 . Moreover, IL-6 inhibition has been recently applied in a clinical setting, and modest protection from GVHD was observed in preliminary studies 68, 69 . The neutralization of IL-6 may result in direct antitumour responses, particularly in multiple myeloma, in which IL-6 supports plasma cell growth 70 . IL-6 inhibition may have more pronounced effects in chronic GVHD, as a direct relationship between IL6 polymorphism and chronic GVHD has been demonstrated 66 and the effects of IL-6-induced T H 17 cells on B cell dysregulation are a hallmark of chronic GVHD.
For their survival and proliferation, T H 17 cells also require IL-23, which is a member of the IL-12 family. The cytokines of this family have shared subunits and a common downstream signalling pathway mediated by signal transducer and activator of transcription 4 (STAT4). In mice, the infusion of IL-23-deficient spleno cytes, or the use of an antibody specific for the p19 subunit of IL-23, decreased GVHD-associated morbidity, while preserving GVT responses. This suggests that IL-23 could be an interesting therapeutic target for controlling GVHD, and it warrants consideration for clinical testing 73 . Neutralizing IL-12 can also be an effective means of preventing acute GVHD 74 . However, administration of high doses of IL-12 at early but not later time points following HSCT protects mice from acute GVHD 75 via an IFNγ-dependent mechanism 76 . Nonetheless, preliminary results suggest that targeting the IL-12-IL-23 axis might be beneficial in patients with refractory acute GVHD 77 .
Targeting T cell co-stimulatory pathways
The important role of co-stimulatory pathways in transplant biology is well established 78 . They are necessary to induce T cell proliferation, cytokine secretion and effector function after T cell receptor activation by antigens. The most extensively studied pathways involve interactions between CD28 and the B7 molecules CD80 and CD86, and between CD40 and CD40 ligand (CD40L). T cell activity is counter-regulated by co-inhibitory mole cules, such as programmed cell death protein 1 (PD1), which binds to PD1 ligand 1 (PDL1) and PDL2.
Initial studies focused on the in vivo blockade of interactions between CD28 or cytotoxic T lymphocyte antigen 4 (CTLA4) and their B7 ligands, CD80 and CD86, using a CTLA4-immunoglobulin fusion protein or B7-specific antibodies 79, 80 . Approaches involving the blockade of the B7-CD28 pathway are limited by the potential adverse effects on T Reg cell survival that would impede the inhibition of acute GVHD. In addition, these approaches block not only the CD28-mediated stimulatory pathway, but also the CTLA4-mediated inhibitory pathway, resulting in an increase in the incidence and severity of acute GVHD. An ongoing trial to prevent acute GVHD is being conducted with a CTLA4-immunoglobulin fusion protein, and future approaches are expected explore a potentially superior approach using a mutated CTLA4-immunoglobulin fusion protein that preferentially inhibits B7-CD28 interactions and not B7-CTLA4 interactions. Finally, studies in rodents and humans have demonstrated that ex vivo blockade of the B7 pathway can induce tolerance and prevent acute GVHD 81, 82 , although this approach is cumbersome. Blockade of CD40L-CD40 interactions was shown to be efficacious in reducing GVHD and, unlike B7-CD28 blockade, it augments natural T Reg cell function in mice 79, 82 . Despite the promise of this approach, clinical applications of a CD40L-specific antibody were limited owing to toxicity associated with endothelial cell and platelet binding 83 . As a result, non-mitogenic CD40-specific antibodies are being developed and, based on rodent data, may prove to be useful adjuvants to achieve tolerization and prevent acute GVHD following HSCT.
Other co-stimulatory molecules that could be targeted to successfully reduce acute GVHD include the TNF family members OX40, 4-1BB, CD30, BTLA, LIGHT and HVEM, as well as the B7 superfamily members ICOS and VSTM3 (also known as TIGIT). Blocking reagents against these pathways (or agonistic reagents for BTLA)
are not yet available for clinical GVHD applications and therefore will not be further discussed 84 . The T cell co-inhibitory molecule PD1 binds to PDL1 (which is primarily expressed by T cells, macrophages, DCs and non-haematopoietic cells in GVHD parenchymal organs) and PDL2 (which is primarily expressed by monocytes and inflammatory macrophages in GVHD target organs). PD1-expressing T cells have been detected at the sites of GVHD, and PD1 blockade results in an IFNγ-dependent increase in acute GVHD severity 85 . Blockade of PDL1 at later time points after HSCT improved GVT effects without exacerbating GVHD in some models, which suggests an avenue for safer application [86] [87] [88] . CTLA4-and PD1-specific blocking antibodies are being tested in the clinic to improve GVT responses after HSCT, although reagents that selectively signal through these inhibitory pathways are not yet available for clinical GVHD prevention or therapy 88, 89 .
Targeting T cell signalling pathways
There are currently several pharmacological agents that target donor T cell activation and are in routine use for allogeneic HSCT recipients. These include calcineurin inhibitors (such as cyclosporine A and FK506), antimetabolites (such as mycophenolate) and lymphocytedepleting agents (such as steroids, anti-thymocyte globulin, CD52-specific antibodies and early posttransplant cyclophosphamide (which selectively induces the apoptosis of alloactivated T cells)) 90 . Although these reagents have proved to be useful for GVHD prevention or therapy, none are entirely efficacious for either application. Here, we focus on approaches that are not in routine use for HSCT recipients but show promise as therapeutic agents for GVHD (TABLE 1) .
Targeting kinases. Protein kinase C (PKC) is crucial for the activation and survival of T cells. PKCθ has been shown to be required for alloreactivity and GVHD induction but not for GVT effects or responses to viral challenge 91 (FIG. 3) . The PKCθ inhibitor AEB071 decreases the production of IL-2 and IFNγ by T cells and extends the survival of rat heart and kidney allografts in primates. Although PKCθ inhibition decreases effector T cell responses, T Reg cell potency is increased, because PKCθ reduces the suppressive capacity of T Reg cells when present at the immunological synapse 92, 93 . This dual role of PKCθ in controlling T cell function makes blocking PKCθ an ideal approach for inhibiting GVHD. Because of the key role for pro-inflammatory cytokines in acute GVHD, inhibition of cytokineinduced signal transduction is an appealing approach for GVHD treatment. Janus kinases (JAKs) are cytoplasmic protein tyrosine kinases that initiate cytokinetriggered signalling events by activating the cytoplasmic latent forms of STAT proteins 94 . In preclinical models, a small-molecule inhibitor of JAK3 has shown great promise in reducing lethality from GVHD without impeding GVT effects 95, 96 . In addition, JAK2 inhibition has been shown to have in vitro tolerogenic effects through its impact on DC-stimulated or allostimulated T cells, while preserving nominal antigen responses 97 . Small-molecule inhibitors of JAK2 or JAK3 may therefore prove to be useful in inducing donor cell tolerance towards the host.
Other tyrosine kinase inhibitors -such as imatinib (Gleevec/Glivec; Novartis), which is commonly used to treat chronic myeloid leukaemia -have been shown to have marked anti-GVHD effects, especially in patients with chronic GVHD 98, 99 . Although the exact mechanism of action of imatinib in GVHD seems to be independent of its inhibition of the platelet-derived growth factor receptor (PDGFR), imatinib represents an attractive agent for suppressing chronic GVHD and preserving GVT responses.
Proteasome inhibitors.
Proteasome inhibitors, such as bortezomib, have recently been used in clinical trials for GVHD on the basis of their capacity to prevent or treat GVHD in mice and their inhibitory effects on cytokine signalling and nuclear factor-κB (NF-κB) activation (FIG. 4) . Bortezomib, even at very low doses, can specifically deplete alloreactive T cells, allow T Reg cell survival and attenuate IL-6-mediated T cell differentiation 100 . Bortezomib can also inhibit APCs by targeting TLR4-mediated activation 101 . In studies in mice, as well as in some clinical studies 102 , administration of bortezomib at early time points after HSCT protected against acute GVHD without impairing engraftment. However, the effect of bortezomib on GVHD depends on the timing of its administration, as delayed administration was shown to cause a TNF-dependent exacerbation of GVHD in the gut, although this may also be due to species-specific differences in sensitivity to the drug 103 . Because bortezomib can preserve or even augment GVT responses by sensitizing tumour cells to cytolytic effector mechanisms, bortezomib and possibly other proteasome inhibitors are attractive therapeutic agents and worth testing in various clinical HSCT settings.
Targeting T cell homing
Modulating the trafficking patterns of alloreactive T cells has been identified as an efficacious means of ameliorating experimental GVHD 104 . Inhibition of T cell homing to inflamed tissues can be accomplished by interrupting one of four key stages of T cell migration: tethering and rolling on the endothelium; chemokine ligand-receptor interactions; adhesion to the endothelium; and migration in response to sphingosine-1-phosphate (S1P). In this section, we review some of the components of T cell homing that have potential applications in the management of GVHD.
Selectins and their ligands. P-selectin is one member of a family of three glycosylated lectins (namely, E-selectin, L-selectin and P-selectin). It is constitutively expressed on the vascular endothelium in the skin and bone marrow, and inducibly expressed by other endothelial cells during inflammation. P-selectin is crucial for the tethering and rolling of T cells on the endothelium. The levels of mRNA encoding P-selectin glycoprotein ligand 1 (PSGL1) are upregulated during GVHD 105 . P-selectin-deficient recipient mice exhibit decreased severity of GVHD in the skin, liver and small bowel compared with control recipients, and this is associated with diminished infiltration of allo activated T cells into the Peyer's patches and small bowel, and with increased numbers of donor T cells in the spleen and secondary lymphoid organs 106 . Blockade of selectinligand interactions can be used to inhibit allo reactive T cell homing, although concerns have been raised about the deleterious effects on wound healing and protection against infection.
Chemokine ligand-receptor interactions. Distinct chemokine ligand-receptor interactions mediate the homing of effector T cells to different tissues. The expression of CC-chemokine receptor 9 (CCR9) by alloreactive T cells facilitates their recruitment into the gut and skin. CCR4 and CCR10 are important for skin homing, and CXC-chemokine receptor 3 (CXCR3) has been shown to attract T H 1 cells to sites of tissue injury. Mice that received a CCR2-deficient CD8 + T cell transplant developed less damage in the gut and liver than mice that received wild-type CD8 + T cells 107 , but the GVT effect was preserved. Moreover, the inhibition of CXCR3 reduced the severity of GVHD in mice 108 . Steroid therapy may alter the levels of several chemokines, such as CXCL9, CXCL10, CXCL11, CCL2 and CCL3, and this differential expression affected the recruitment of T cells to the gut but not the liver 109 . Although there is no direct evidence from animal studies on the role of CCR9 in GVHD, CCR9 polymorphisms have been linked to GVHD severity in humans 110 , making this cytokine a potential target for future clinical trials. However, one limitation of the use of chemokine receptor antagonists, such as CCR5 antagonists, is the possible interference with T Reg cell recruitment to GVHD target organs 104 .
High-affinity integrins. The importance of high-affinity integrins in inflammatory conditions, including GVHD, has only recently become greatly appreciated 111 . For example, natalizumab -a humanized monoclonal antibody specific for α4 integrin -has been approved for the treatment of patients with multiple sclerosis but, in some cases, resulted in a progressive demyelinating disease. α4β7 integrin has been shown to have a pivotal role in the homing of alloreactive cells to the gut, and inhibition of β7 integrin can substantially moderate the effects of acute GVHD in the gut, while sparing GVT effects 112 . It is this level of tissue specificity shown by integrins that makes them interesting targets for future GVHD therapy. It is possible that clinical trials of natalizumab in GVHD, if performed, will not be associated with progressive demyelinating disease, as these patients do not have the underlying inflammation in the central nervous system that is present in patients with multiple sclerosis.
Sphingosine-1-phosphate receptors. FTY720 is a highaffinity agonist for four of the five known S1P receptors, which are crucial for cell survival, cytoskeletal rearrangements, cell motility and cell migration. FTY720 induces S1P receptor internalization, which renders the cells unresponsive to the serum lipid S1P. FTY720 exerts its immunomodulatory effects primarily by sequestering lymphocytes in secondary lymphoid organs and preventing them from circulating to peripheral inflammatory sites. Acute GVHD mortality is decreased by FTY720, whereas GVT effects are not prevented 113, 114 , although the mechanism is unclear. In one study, FTY720 was shown to differentially modify the migration of effector T cells to lymphoid organs, but it did not cause the retention of effector T cells in the lymph nodes or prevent early migration of effector T cells into GVHD target tissues 115 . Rather, FTY720 reduced the number of splenic DCs and the frequency of responding donor T cells at early time points following HSCT. FTY720 is therefore a potential candidate for GVHD prevention or therapy, although preliminary studies in solid organ transplantation did not show a therapeutic benefit.
T Reg cells and tolerogenic DCs
Natural T Reg cells. Natural T Reg cells -which are defined by their expression of CD4, CD25 and the transcription factor forkhead box P3 (FOXP3) -suppress auto reactive lymphocytes and control innate and adaptive immune responses [116] [117] [118] . T Reg cell impairment is associated with a loss of tolerance, as well as with auto immunity and chronic GVHD 119 (FIG. 5) . In preclinical models, adoptive transfer of natural T Reg cells was highly effective at suppressing acute GVHD [120] [121] [122] and improving immune recovery 123, 124 . Surprisingly, GVT responses were preserved, which was possibly due to the retention of cytolytic T cell function or differences in T Reg cell versus effector T cell homing patterns 125 . Two Phase I clinical Nature Reviews | Immunology The infusion of mesenchymal stem cells (MSCs) for the treatment of GVHD has had mixed results. However, the transfer of donor-derived T Reg cell populations that are expanded ex vivo has been more promising. Furthermore, in preclinical models, the infusion of myeloid-derived suppressor cell (MDSC) populations that are expanded ex vivo using G-CSF (granulocyte colony-stimulating factor) and GM-CSF (granulocyte-macrophage colony-stimulating factor) with or without IL-13 has been shown to be a feasible approach with anti-GVHD effects. Injection of pegylated arginase 1 may have the same benefit and be more practical. CTL, cytotoxic T lymphocyte; IFNγ, interferon-γ; iNOS, inducible nitric oxide synthase; LPS, lipopolysaccharide; PDL1, PD1 ligand 1. trials using T Reg cells for the prevention of acute GVHD have been reported. Human T Reg cell populations that were expanded from umbilical cord blood before transplant substantially reduced the incidence of acute GVHD compared with historical controls 125, 126 , although the achieved ratios of T Reg cells to effector T cells were suboptimal based on findings from GVHD mouse models. Improvements in the ex vivo production of natural T Reg cells should permit the expansion of large numbers of otherwise hypoproliferative natural T Reg cells 127 . In another study, freshly isolated T Reg cells from haploidentical donors almost completely prevented acute GVHD in a mouse model when transferred together with effector T cells at numbers that typically cause acute GVHD 123 . New methodologies to generate antigenspecific natural T Reg cells are likely to be tested in future trials as a means of restricting natural T Reg cell-mediated suppression to acute GVHD while sparing GVT responses. Given the potent effects of natural T Reg cells observed in preclinical studies and the encouraging preliminary data from human clinical trials, the infusion of natural T Reg cells could provide a degree of specificity in acute GVHD prevention that is not possible with T cell depletion or globally immunosuppressive drugs.
The cytokine IL-2 has a crucial role in the proliferation of T Reg cells and effector T cells. Its effect on T Reg cell proliferation may be one reason for the lack of a robust therapeutic response to IL-2 inhibitors observed in a Phase II randomized trial in acute GVHD 36 . Chronic GVHD was ameliorated in some patients by a low dose of IL-2, and this was associated with increased T Reg cell numbers. Although it remains to be determined whether T Reg cells were essential for the beneficial effect 102 , an involvement of T Reg cells is consistent with mouse studies in which IL-2 given with the mammalian target of rapamycin (mTOR) inhibitor rapamycin (also known as sirolimus) resulted in protection from acute GVHD as a result of the expansion of T Reg cell populations 128 . Although IL-2 was originally thought to be deleterious in GVHD owing to its ability to promote effector T cell function, the effects of low doses
Tolerogenic DCs
A subpopulation of dendritic cells that can promote antigen-specific peripheral and central tolerance by inducing antigen-specific regulatory T cells, T cell anergy and the deletion of antigen-specific cytotoxic T cells. 
Mixed lymphocyte reaction

Alternatively activated macrophages
(Also known as M2 macrophages). Macrophages that are stimulated by interleukin-4 (IL-4) or IL-13 and express arginase 1, the mannose receptor CD206 and IL-4 receptor-α. Pathogenassociated molecular patterns expressed by helminths may also drive the alternative activation of macrophages. Tolerogenic DCs. DCs do not always promote immune responses and can have tolerogenic functions and inhibit GVHD in mice 130, 132 . Tolerogenic or regulatory DCs can be obtained by exposing bone marrow-derived cells to GM-CSF (granulocyte-macrophage colony-stimulating factor), IL-10, TGFβ and then LPS or can be isolated from a mixed lymphocyte reaction supplemented with TGFβ and retinoic acid. Infusion of tolerogenic DCs has been shown to rescue animals from lethal acute GVHD, and this was associated with the generation of induced T Reg cells 132 . In addition, correlative studies in patients have indicated an association between reduced incidence of chronic GVHD and a high DC content in the graft 133 .
Mesenchymal stem cells
Other immunomodulatory cell therapies NK cells and NKT cells. Donor NK cells have also been shown to have a role in the inhibition of acute GVHD. Preclinical studies indicated that donor NK cells can suppress acute GVHD and promote GVT responses 134 . Subsequent studies have shown that donor T cells exhibit less proliferation, lower CD25 expression and decreased IFNγ production in the presence of donor NK cells and cytokine-induced killer cells, which are a mixture of NK cells and highly activated CD8 + T cells that mediate MHCunrestricted cytotoxicity 134 . 'Third-party' NK cells are being designed to investigate the clinical potential of such an approach 135 . Such an effect has been indirectly shown in clinical studies in which an infusion of NK cells with HSCT was associated with decreased GVHD occurrence and severity compared with HSCT alone 136 . Furthermore, it has been demonstrated that signalling by the killer cell immunoglobulin-like receptor (KIR) family is important in determining the activity of NK cells and the outcome after allogeneic HSCT for acute myeloid leukaemia (AML) 137 . This has spurred interest in optimizing NK cell use not only to suppress GVHD but also to promote GVT responses, as haploidentical NK cell transfer can increase GVT responses in patients with AML 138 . Strategies to promote this effect through concurrent administration of NK cell-stimulating cytokines (such as IL-2 or IL-15) are being examined, together with the potential inhibitory effects of HSCT immunosuppressive regimens on NK cell activity and recovery.
A population of cells that co-express NK cell and T cell markers, known as NKT cells, has also been shown to control GVHD in mice in an IFNγ-and IL-4-dependent manner 52 . An NKT cell-dependent mechanism has been proposed to explain the beneficial effects of a nonmyeloablative conditioning regimen involving total lymphoid irradiation and anti-thymocyte globulin infusion in clinical trials 139 . In addition, the in vivo activation of NKT cells -in particular, the population of invariant NKT cells -with glycosphingo lipids such as α-galactosylceramide has been shown to inhibit GVHD in mouse models. A liposomal form of this compound is currently been tested in clinical trials. However, such an approach has recently been chall enged, as early administration of a synthetic form of α-galactosylceramide, known as KRN7000, resulted in hyperacute GVHD in mice 140 . Thus, it remains to be determined whether NKT cell-based therapeutic approaches will be useful in the long term. 141, 142 . MDSC populations can be expanded in vitro and can suppress T cell function by expressing enzymes that regulate essential amino acid metabolism (namely, arginase 1 and indoleamine 2,3-dioxygenase (IDO); see below), by releasing soluble mediators (such as IL-10, reactive oxygen species or nitric oxide), through direct cell-to-cell contact, and by inducing the generation of T Reg cells 143 , although their effect on T Reg cells is variable 139, 140 . Thus, MDSCs share features with alternatively activated macrophages (also known as M2 macrophages). Preclinical studies have shown that MDSCs can suppress acute GVHD 144, 145 . Moreover, in one study 144 , in vivo arginine depletion could also be accomplished through the use of a drug, pegylated arginase 1, suggesting a new pharmacological approach to acute GVHD prevention.
MDSCs
MSCs. Bone marrow-derived mesenchymal stem cells (MSCs) are a group of heterogeneous plastic-adherent cells with the capacity to differentiate in vitro into osteo blasts, adipocytes and chondroblasts. MSCs have a wide range of immunosuppressive and immunomodulating effects on innate and adaptive immune cells 146 . MSCs may have a protective effect against GVHD 147 , although this effect has not been seen consistently in mouse models 148 . Results of clinical trials are also confusing, as earlier trials showed substantial benefits, whereas two recent Phase III trials with at least one source of MSCs did not show any benefit 149, 150 . Differences in manufacturing and defining MSCs, in their expression of homing receptors and in the type of GVHD injury may all contribute to the difficulty in comparing results between laboratories and clinical outcomes.
Targeting intracellular pathways
There are several other intracellular pathways that show potential as targets for therapeutic manipulation in GVHD. These include IDO-mediated immune regulation, Notch signalling and DNA methylation (FIG. 4) .
IDO-mediated immune regulation.
IDO is the first and rate-limiting enzyme in the catabolism of the essential amino acid tryptophan. The depletion of tryptophan and/ or the accumulation of tryptophan metabolites (termed kynurenines) through the activity of IDO inhibits T cell proliferation and leads to T cell death. IDO is produced by some alternatively activated macrophages and by other immunoregulatory cells. More importantly, tryptophan starvation and the presence of kynurenines can induce the conversion of naive T cells into induced T Reg cells 151 . GVHD induces the expression of IDO in the gut, but the timing of this expression is too late to avoid disease 152 . In rodents, both APCs and epithelial cells contribute to the inhibition of GVHD by expressing IDO. Furthermore, in patients who received HSCT, IDO expression was detected not only in CD16 + macrophages and DCs, but also, to a greater extent, in a subset of CD4 + T cells, the frequency of which correlated with acute GVHD severity 153, 154 . IDO expression can be induced during HSCT by administration of a TLR7 agonist through an IFNγ-dependent mechanism. Alternatively, kynurenines can be infused, simulating the effects of IDO induction. Both IDO induction and kynurenine administration represent new therapeutic approaches for acute GVHD 155 . However, GVT effects in the setting of induced IDO expression need to be assessed, as does longterm tolerance induction in the absence of continuous tryptophan starvation or kynurenine administration. Notch inactivation. Notch signalling controls cell fate and tissue homeostasis. Notch family receptors interact with ligands of the jagged and Delta-like families and, following proteolytic cleavage by γ-secretase, the Notch intracellular domain translocates to the nucleus to exert its biological effects. Recent studies have indicated that the inactivation of Notch signalling in donor CD4 + T cells inhibits acute GVHD while preserving GVT responses 156 . On the basis of highly encouraging preclinical data, several pharmacological methods of Notch inactivation are now entering clinical trials, and this may prove to be an effective strategy to inhibit acute GVHD.
Modulation by DNA hypomethylation and hyperacetylation. Hypomethylating agents such as azacitidine can prevent acute GVHD in mice without interfering with GVT effects 157 and can increase T Reg cell numbers in patients who receive HSCT 158 . Selective depletion of alloreactive T cells and preservation of T Reg cells following extracorporeal photopheresis using a photoactivatable DNA mutagen was also seen in preclinical models of acute GVHD and in patients with chronic GVHD 159, 160 . Similarly, inhibition of histone methylation using 3-deazaneplanocin A has been shown to arrest on going acute GVHD in mice by activating the proapoptotic gene BIM, which results in selective apoptosis of alloantigen-activated effector T cells and, importantly, preserves GVT effects 161 . The prospective clinical testing of hypomethylating agents, in particular for GVHD prevention, deserves strong consideration for future trials.
Histone deacetylase (HDAC) inhibitors, which are currently in clinical trials for GVHD, modify histones and chromatin and have been shown to have a protective effect in acute GVHD 162, 163 . This effect is mediated through a mechanism involving the suppression of host APCs and increased IDO expression and T Reg cell numbers 163 . In addition, HDAC inhibitors may modulate T cell activation by inhibiting STAT3 phosphorylation 164, 165 . The use of a small-molecule inhibitor of STAT1 (a transcription factor that inhibits FOXP3) could also be exploited as a means of promoting induced T Reg cell conversion and the expansion of natural T Reg cell populations, although such reagents are not currently being tested for such purposes in the clinic 166, 167 .
Immune modulation by statins. Finally, statins have been shown to reduce GVHD in mouse models through their immunomodulatory effects on APCs and T cells. These effects are thought to be mediated by a decrease in the production of l-mevalonate and its downstream iso prenoid metabolites 168 . However, a retrospective analysis of transplant recipients who were taking statins has shown that such a benefit may occur at the cost of increased cancer relapse owing to nonspecific effects of statins on GVT responses 169 .
Conclusions and future directions
Despite improvements in our understanding of transplant immunology and clinical and supportive care, both acute and chronic GVHD remain a clinical challenge and a major cause of morbidity and mortality for HSCT recipients. Systemic corticosteroid therapy, despite its major shortcomings, remains the standard primary therapy for GVHD. New and improved therapies are therefore desperately needed, particularly in cases of steroid-refractory chronic GVHD. Improvements to the preclinical models, particularly for chronic GVHD, are also needed, as conditioning regimens and the patient populations receiving allogeneic HSCT are constantly changing.
Most of the current therapeutic approaches that are routinely used for GVHD are broad-spectrum approaches that target T cells and are therefore likely have a negative impact on GVT responses as well as immune reconstitution. More selective approaches that specifically influence the activation, survival or function of alloreactive T cells should avoid some of the adverse side effects of global immunosuppressive therapy. The current and potential future approaches for the prevention or treatment of GVHD can thus be divided into three broad categories. First, there are approaches that may negatively affect GVT responses, such as the systemic use of steroids, the inhibition of co-stimulation and the use of calcineurin inhibitors. Second, there are strategies that can provide a relative preservation of GVT responses versus GVHD, such as the use of IL-21-specific antibodies and cellular therapies with natural T Reg or induced T Reg cells. Third, there are treatments that may improve 
Extracorporeal photopheresis
A form of photodynamic therapy in which mononuclear cells are separated from blood by leukopheresis and chemically treated with a photosensitizer such as 8-methoxypsoralen, exposed to ultraviolet light, and re-infused into the patient. The mechanism of action has been proposed to involve alloreactive T cell depletion and T Reg cell induction.
Statins
A family of inhibitors of hydroxymethylglutaryl-CoA reductase (HMG-CoA reductase), an enzyme that catalyses the conversion of HMG-CoA to l-mevalonate. Statins are mainly used as cholesterol-lowering drugs, but they also have immunoregulatory and anti-inflammatory properties.
l-mevalonate and its metabolites are implicated in cholesterol synthesis and other intracellular pathways.
GVT effects, such as those that are directly toxic to the tumour (for example, proteasome inhibitors and IL-6-specific antibodies) or cellular approaches (for example, NK cell infusion and modified donor lymphocyte infusions). As examples of modified donor lymphocyte infusion strategies, CD8 + T cell-depleted donor lymphocytes have been used by several investigators and, more recently, a suicide gene was incorporated into donor T cells as a safety switch to prevent GVHD by inducing apoptosis in transgene-expressing alloreactive T cells 170 . Potential deleterious effects of some GVHD therapeutic approaches on immune cell engraftment and immune reconstitution will also affect their clinical applicability.
Although no single preclinical approach has proven to be uniformly efficacious in preventing GVHD and retaining GVT responses, the strategies used in recent clinical studies based on findings in mouse models of GVHD are particularly noteworthy. These approaches include: natural T Reg cell infusion, memory T cell isolation, suicide gene transfer, total lymphoid irradiation plus anti-thymocyte globulin, proteasome inhibitors, HDAC inhibitors and IL-21-specific antibodies. Novel and unique approaches, such as the inhibition of neovascularization, which is an early event in the inflammatory phase of acute GVHD, may also prove to be promising 171 . Moreover, as our understanding of basic immunology advances, there may be cause to re-analyse approaches for treating GVHD. For example, our understanding of the dominant role of IL-2 in the proliferation of T Reg cells rather than effector T cells informs the possible therapeutic application of low-dose IL-2 in chronic GVHD. In addition, by capitalizing on reagents that are already in use in the clinic for other purposes, those interested in preclinical modelling and clinical applications should have a rich source of new strategies to prevent or treat GVHD in the future.
